[Turn] Pfizer CEO Yang!I had 4 stitches my own vaccine, but I still did not prevent it

Source: Siqi Club/Four Leaf Grass

On August 15, local time, Pfizer's official website issued a statement saying that the company's chief executive officer Albert Bourla's new crown virus test results were positive.

Aberle said that he had inoculated 4 doses of Pfizer/Biontech's new crown vaccine. At present, it feels good, but there is mild symptoms that are being isolated and following public health prevention measures. In terms of treatment, he said that he had started taking the company's new crown oral medication Paxlovid, and I believe it would recover quickly.

In addition, he has not forgotten the new crown oral medication. "At present, Paxlovid has obtained the emergency use authorization of the FDA (US Food and Drug Administration), which can be used to treat it with more than 12 years old, weighs more than 40 kg, and the new crown test is positive. , High -risk groups with mild to moderate symptoms. "

According to media analysis, as a company that created the most widely used vaccine worldwide, CEO turned out to be a new championship, which is quite ironic. However, this also proves that the proportion of new variants of new coronal viruses is significantly higher than the previous strains, and the public may require the public to vaccinate specific variability or specific subtypes.

According to data, Alber is a doctor of veterinary medicine. He worked in Pfiz for nearly 25 years and officially served as Pfizer CEO on January 1, 2019. Earlier, he also served as the president of Pfizer's global vaccine, Tumor and Health Pharmaceutical Department, as well as the president and general manager of Pfizer's core product business.

The new crown vaccine's half -year income exceeds $ 22 billion

In the statement, Aberle mentioned the new crown vaccine that he had vaccinated and the oral medicine that was taking. It was Pfizer's heavy product -MRNA new crown vaccine Comingaty and new crown oral medication Paxlovid. These two products directly drove the soaring performance of Pfizer. Last year, Pfizer retracted the throne of the "First Medicine Factory in the Universe".

The Pfizer semi -annual report shows that the company achieved a total revenue of 53.4 billion US dollars in the first half of this year, an increase of 60%year -on -year; net profit was 17.769 billion US dollars, an increase of 70%year -on -year. And this is mainly due to the MRNA vaccine COMIRNATY sales revenue, reaching $ 22075 billion.

In the first half of this year, COMIRNATY's market share has gradually expanded, and more than 3.6 billion vaccines have been distributed to 180 countries and regions. In June of this year, Pfizer and the US government have reached new agreements, providing an additional 105 million new crown vaccine, with a value of US $ 3.2 billion.

In addition, the revenue of the new crown oral medication PAXLOVID in the first half of 2022 was US $ 9.585 billion, of which the revenue in the second quarter was US $ 8.115 billion, contributing a lot. This benefits from the extensive popularity of this product in the United States and the expansion of international market access.

At present, Pfizer and Biontech are trying to expand their applicable people in various countries and strengthen needles. At the same time, they also developed a di -valence candidate vaccine against the new crown Omircong mutation BA.1 and BA.4/BA.5 to continuously enhance the ability to fight against mutation. According to Biontech, the company is expected to be delivered to two types of Omikon adaptive vaccines as soon as October.

However, with the continuous improvement of the global new crown vaccine vaccination rate, market sales have gradually stabilized, and the decline in vaccine sales will inevitably.

In 2022, Pfizer's revenue guidance remained at $ 98 billion-$ 102 billion, of which the expected income of vaccine Comingaty was US $ 32 billion, and the new crown oral medication PaxLovid was $ 22 billion.

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -